Good morning, everyone. My name is Latif, and I will be your conference operator today. At this time, I would like to welcome everyone to the Sun Life Financial Q1 2022 Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a Question and Answer session. The host of this call is Yaniv Bitton, Vice President, Head of Investor Relations and Capital Markets. Please go ahead, Mr. Bitton.

Thank you. And good morning, everyone. Welcome to Sun Life's Earnings Call for the First Quarter of 2022. Our earnings release and the slides for today's call are available on the Investor Relations section of our website at sunlife.com. We will begin today's call with an overview of our first quarter strategic highlights from Kevin D. Strain, President and Chief Executive Officer. Following Kevin's remarks, Manjit Singh, Executive Vice President and Chief Financial Officer, will present the financial results for the quarter. After the prepared remarks, we will move to the question-and-answer portion of the call. Other members of management will also be available to answer your questions this morning. Turning to Slide 2. I draw your attention to the cautionary language regarding the use of forward-looking statements and non - IFRS financial measures, which form part of today's remarks. As noted in the slides forward-looking statements may be rendered inaccurate by subsequent events. And with that, I'll now turn things over to Kevin.

Thanks, Yaniv. Good morning to everybody on the call today. Turning to slide four, Sun Life delivered a solid start to 2022, driven by our diversified business model, prudent risk management practices, and strong capital position. Reported net income of 880 -- $858 million we found 8% from prior year. An underlying net income of $843 million was broadly in line with last year. COVID-19 continued to impact our businesses and while headwinds from COVID-19 remain, as of March, we serve to see an improvement in U.S. COVID related death, which should drive more favorable mortality experience in the second quarter. We continue to watch the trends closely. And in most of our markets, we're seeing a transition as COVID becomes less of an impact, and populations have increased immunity. This doesn't mean COVID is over, but it does suggest smaller impacts in terms of claims and business interruption going forward. We're also pleased that in both of our markets are offices are now open, and we have people working flexibly, both in the office and virtually as their day allows. With the war in Ukraine impacting economic conditions, supply chains, and energy costs, the world is now facing new challenges with heightened geopolitical pressures and central banks raising rates to curb higher-than-expected inflation. These challenges create uncertainty. But our diversified business fix and strong risk management will enable us to manage through these headwinds. We're expecting pressure on equity markets, credit and expenses due to inflation. But higher interest rates particularly at the long end of the curve, should help drive profitability. And the ongoing growth in our businesses also supports our medium-term objectives. Our capital position remains strong. With LICAT ratio of a 143% at SLS. We're also pleased to announce a 4.5% increase to our commentary dividend,…

Thank you, Kevin. And good morning, everyone. Slide 8 provides an overview of our first-quarter results. Sun Life delivered solid results amidst the challenging operating environment with good momentum across all of our business groups. Reported net income in the quarter was $858 million down 8% reflecting less favorable market-related impacts. Underlying net income of $843 million, an underlying earnings per share of a $1.44 were down modestly from the prior year. Earnings for the quarter were supported by strong fundamental business activity, partially offset by COVID related impacts in the U.S. and Asia. Earnings from surplus of 65 million was lower this quarter, primarily driven by higher external debt costs and lower AFS gains. With rising rates and wider spreads, contribution from AFS gains are expected to moderate. At the same time, these factors can also provide trading opportunities which can generate investment-related gains. Underlying return on equity was 14% in the quarter. Assets under management were 1.35 trillion at the end Q1, this was down from the end of last quarter, reflecting declines in equity markets and rising interest rates. Both value per share was up 7% over the prior year, excluding impacts and other comprehensive income, which includes foreign currency translation and changes in the available for sale. Book value per share was up 11% our capital position remains strong with LICAT ratios of a 143% at SLS and a 123% at SLA. And financial leverage ratio of 25.9%. Let's turn to our business group performance starting online on slide ten with MFS. MFS reported net income of us $228 million, which was up 23% from the prior year, reflecting lower fair value changes on share-based payment awards. Underlying net income was up 4% driven by higher average net assets. And MFS generated the solid pre -tax…

Thank you, Manjit, to help ensure that all of our participants have an opportunity to ask questions this morning. I would ask you to limit yourselves to one or two questions and then re-queue with any additional questions. I will now ask our Operator to pull the participants.

Thank you. [Operator Instructions] Please stand by while we compile the Q&A roster. Our first question comes from Meny Grauman of Scotia Bank. Your line is open.

Hi, Dan. I just wanted a little bit more detail on your look for mortality in the U.S. It was noted that it's improving. When do you expect it to actually normalize? And if we look at the stop-loss business as well, when do you expect COVID related impacts to fully normalize there as well?

Good morning, Meny its Dan Fishbein. Thanks for the questions. In terms of mortality, we're certainly seeing significant improvement as you saw with the first quarter was better sequentially than the fourth quarter. Most of that improvement occurred in the month of March. So if you look -- break it down by the months we're starting to see steady improvement month over month. I can share that April improved from there and so far in May, we see further improvement. If you look at external estimates, there were about a 160,000 total deaths in the U.S. in the first quarter and the external estimates are predicting an average of about 30,000 total population deaths in the second quarter. So that's a reduction of about 80%. You should expect to see significant improvement in our mortality certainly reflecting that. And for your question is to when will it completely return to normal? Unfortunately, we don't think that COVID is going away completely and we do think there will be elevated mortality for a significant period of time. We are building that into our pricing as we've mentioned before, it does take a full 3 years to cycle through the entire book of business. We started increasing our pricing at the end of last year.

But certainly we have ways to go until that pricing catches up, but that's probably about a mid-single-digits impact. Our hope, of course is that we will remain at the current relatively low level. But we're likely to see some peaks and valleys in that going forward. We are at 325 deaths a day at the moment on a seven-day average in the U.S. and that compares with numbers in the first quarter that reached as high as 2700 a day. So clearly, mortality as of lower level now. On stop-loss as you noted, we had quite favorable experience in the first quarter. About 1/2 of that was due to tailwinds related to COVID delays in care. But about half of that was related to underlying favorable underwriting results. We do think over the next few quarters, utilization and hospitals will return close to normal levels, but that will take a few quarters. Our own underlying good results those should persist.

Thanks for that. And then just maybe just a follow-up on the pricing and we talked about it last quarter, but just from a competitive point-of-view, what are you seeing out there in the market is -- are most of your competitors viewing it the same way as you in terms of the necessity to raise pricing, COVID is not going away or is there -- basically what's going on in the market now relative to the pricing that you're pushing through?

Generally, our sense is that mid-single-digit range is what the industry is doing. There's always exceptions. It remains a highly competitive market and so on a case-by-case basis, we still see pretty intense competition. But we believe that our level of increase is consistent with the market.

Thank you.

Our next question comes from David Motemaden of Evercore ISI. Your line is open.

Thanks. Good morning. Just had a question for MSS. Kevin, could you just talk about the margin outlook there? And how you think you can manage through the market volatility given some of the inflationary comments you made in your prepared remarks that may make it more difficult to manage the expense base than in the past?

Well thanks, David. I'm going to let Mike answer the question on that.

Good morning, David. I mean, clearly, as we made our way through Q1 year-over-year results were up pre -tax was up over last year, but as A&A is continued to come down in the second quarter relative to last year. That's going to obviously have an impact on the profitability in the margin. The guidance we provide over time, is it a normal environment we think a net margin in the 35 to 40 range we were at the higher end of that. And well over that it's late last year, given the market at all-time highs. And so what you'll see in the expense side would naturally comes down as those variable. Those things that are tied to profitability like compensation, asset-based fees that we've paid distributors. And so we're still comfortable with that range. But you should expect that if the market stays where it is for the year, obviously the margins going to be pressured relative to last year.

Yes, got it. That makes sense. And then another question just for Dan, just in terms of the non-COVID long-term disability experience, could you just talk about what you're seeing? What you saw in the quarter, your expectations, and if you're re-pricing the business or how you're repricing the business in response to that?

Yeah. We definitely aren't seeing some elevated morbidity in long-term disability now a significant amount of that is COVID-related. There is some we do have some long COVID cases. The good news is although this is a little more anecdotal, we are seeing recoveries in long COVID. So those disability don't seem to be long-term persistent. But there is some overall elevation in LTD experience that's non COVID-related, as well as it's modest, but it's real. We think that's related to some of the second order effects of the pandemic, including the recent moves by some employers to require employees to return to the office. We think some of that will persist, but maybe not long term, that maybe a few quarters impact as the labor market and employers find their equilibrium of how they want to work in the future. However, like in our group life business, we are raising prices in our disability business as well to reflect these impacts. Coincidentally, it's the same mid-single-digits kind of range. And we're generally seeing that in the marketplace as well. Same effect though you see case-by-case intense competition. But we do believe competitors are raising rates by a similar amount.

Got it. Thanks for that color.

Thank you. Our next question comes from Gabriel Dechaine of National Bank. Your line is open.

Good morning. Just yield enhancement gains. Big uptick this quarter from what we've seen in the prior few quarters. Over a $100 million, can you tell me what that number would look like on their IFRS 17?

Gabriel, its Manjit. Good morning. As you know, the overall investment activity gains are largely driven by a couple of things. The overall market conditions and our available funds that we have to put into the market to invest. And obviously we had some pretty good conditions in the quarter and our investment teams took advantage of that to invest in good quality, higher-yielding assets, and that's what drove the gain in the quarter. On the IFRS 17 question, we'll handle that in our May 31st session that we have upcoming so we'll give you more details then.

Would it be materially lower?

I guess I gave -- it will give you more details on May 31st.

And I guess this quarter -- I mean, in the current accounting, this quarter probably seeing similar spread pick up opportunities, right?

Yeah. It'll depend on the market availability as well as the funds that we are putting into the market. So far the market is continuing to provide some opportunities.

Thank you. Our next question comes from Scott Chan of Canaccord. Your line is open.

Good morning. For Manjit or Steve on SLC. We really appreciate the increase -- updated disclosure on that statement. So specifically, FRE [Indiscernible] net income target that you update as last quarter. And maybe -- maybe going down to the margin, we don't think we're prepared to do an FRE target. But margins were in the low twenties for [Indiscernible] and you talked about the 30-35 percent operated target by 20-25, would it be safe to sales lead offering margin would be aligned with that operating target or was there be nuances up or down?

Thanks guys. This is Steve. I can answer that. I think over time you're going to see the main difference between FRE related earnings and operating income is going to be that under -- between those two, you're going to have performance fees and income from seed investments that will be the difference we are putting in income and FRE margin. I think that those over time you're going to see more performance fees as the business grows. I think you're going to see more seed capital investments. So you'll see more seed related income. I think with our margin for the quarter, we're on track for the margin parts that we set out for 2025. And some of the fluctuation you'll see in margin quarter-to-quarter, even year-over-year can relate to things like catch-up fees, which could impact the margin or marketing costs. We have a big fundraising and you expense marketing costs and a given quarter, but you haven't earned the revenue yet because that will play out over time as the money is invested. So you are going to going to see you a bit of fluctuation in that, but we do think we're on target for -- on track for our targets.

And where have you seen work well, seeing what's happening in the public markets, but the private markets are your all platform. Can you maybe describe any market headwinds that you're seeing or perhaps tailwinds in the current environment?

You know I think It’s a bit too early to see what the long-term impact is on either the underlying portfolios and are different asset classes or on the fundraising. I would say the first quarter fundraising, we feel really good about we haven't really seen examples of investors pulling back from these asset classes. Yet, if market volatile. Really picks up, you could see that we haven't seen it yet. I think the market environment actually can cut both ways. I mean with rates going up and spreads going up that could have an impact on asset classes like real estate. Though I would say real estate portfolios were up strongly during the first quarter. But on the flip side, with raising rates. We’ve actually seen money coming back into our fixed income portfolios as pension funds is actually helps to fund rate funding ratio for pension funds. And in some cases there are more willing to now put more money back into fixed income at higher yields. So little too early to see with the longer-term impacts our, but I think it cuts a couple of different ways.

Thank you very much.

Thank you. Our next question comes from Paul Holden of CIBC. Your question, please.

Thank you. Good morning. So going back to the U.S. group and the conversation around the normalization of experience. And perhaps mortality staying a higher for longer. Is there anything in your mind that's changed your profit margin expectation, excluding the DentaQuest acquisition?

Good morning Paul, it's Dan Fishbein again. There really isn't. Obviously the fact that we may see somewhat elevated mortality, although certainly nowhere near what we've been seeing in over the past couple of years, in the short-term could affect margins. But as we reprice for that, and we should be able to reprice for that, that would put us back at the same margins. As I mentioned in the last call, overall, our group benefits business is in the best condition that it's ever been. Sales are strong, persistence has improved, and we are getting the pricing that we ask for that we need. We've had significant gains in expense efficiencies, introduced new products, capabilities, and digital programs into the marketplace. All of those things position us very well in the previous margin guidance that we've given. Those 7% or greater is still very much our expectations absent COVID effects. But the fundamentals of the business remain strong and remain as they were.

Great. Thank you. And then capital allocation question for [Indiscernible]. He noted a couple of strengths of the business, which is obvious, we're seeing valuations drop. Is this leading to increased potential capital deployment options, and would you be willing to be opportunistic in this type of environment with capital deployment?

Well thanks, Paul and, as you know, we've talked about in--in other quarters our priorities for capital deployment remain largely the same, right? We're focused on supporting our organic growth and our organic growth target for EPS is 8% to 10% and continue on that. We're committed to supporting our dividend and the dividend growth and we've outlined that for the 50% of underlying earnings and you saw the 4.5% increase in our dividend this quarter. Of course, we've been able to deploy into M & A that improves either scale or adding new capabilities. Like the DentaQuest that's going to be closing soon and that's going to use a big chunk of Capital. But we're always looking sort of forward at what the opportunities are across the three of those. And we all, we always keep buybacks as an alternative if we see that the level of capital is more than what we need, we give it back to shareholders. So at this point in time, it's a combination of economic conditions, uses we have for capital and we continue to look at all of the uses.

Great. Thank you.

Thank you. Our next question comes from Doug Young of Desjardins Capital Markets. Your line is open.

Good morning. And I guess this question is for Jacques, I think group morbidity experience in Canada was adverse once again. And I think that's been recurring theme for a while here, just -- and I know that you've you're taking actions, putting through price increases. Just wanted to get a better sense of what you're seeing on the ground and what level of price increases are flowing through. And when we might see that turn?

Hey Doug. Thank you for the question. This is Jacques. You're right on the morbidity experience is unfavorable in the quarter and just do with GB disability as you say. I might just remind you that we've got two things we're looking at. One is the volume of cases which called the incidence. And then how long or the duration of cases before people get back to work. In May 2019, we decided to increase our pricing quite materially. And that was to do with the fact that when it comes to incident, our view in our models were suggesting that the trend up was what I would call durable trend. And so we took action. And today I can tell you, Doug that the incident is in line with our pricing and our expectations. So the issue is indeed, as you pointed out, on the duration. Now, unlike incidence on duration we don't see this for now as a durable trend. It's taking -- part of this is COVID, access to care has been an issue. People getting surgeries and so on. So our view remains that this is temporary. Of course, if signal were to change and suggest that has a more durable pattern to if we would take action. But at this stage, we think that's not the case.

Okay. And then just a question on the Asia business, there is a large India state for an insurance company in India going public and which is interesting to talk about. I'm just curious. What if any of this has impact-wise on your Viewpoints in India or your India life insurance business?

Can start and then in grids also, its Kevin, Ingrid is also on the calls like can let her add some color. The LIC is the largest provider of insurance in the country. It's an amalgamation in 1956/1957 of all the insurance companies, I think being a public company provides a level of discipline and transparency which is probably long-term good for the industry. We really like our partnership with the -- to be in the group. We have a strong position in both the insurance company and the asset management company. I think that doesn't change from the LIC going public at all. They were already a big competitor. And so it's -- we're still optimistic about India and we think there's great potential there. I don't know if Ingrid, if you wanted to add anything?

Other than you would have seen you still had relatively strong sales in the quarter and we excited about the business north of the digitalization that's taking place. And we are well-positioned both in loss and asset management.

[Indiscernible]

You'd see that the evaluations in India are quite high and I would note that the P multiples are high. And that shows you, I think the long-term value creation opportunity in India.

Great. Thanks.

Thank you. Our next question comes from Mario Mendonca, TD securities. Your line is open.

Good morning. Review back to policyholder expenses -- the policyholder experience. I noticed that expense experience was positive this quarter. I look back at the model to see the last time that was true, I think I have to go back to Q3 2019, though, you talk a little bit about why it would flip signs this quarter and then on a related note, the other expense or the other experience was rather negative. I'm referring to the minus 41 million. Is that expense -- I mean, should we be looking at those two together is what I'm getting at.

Good morning, Mario, it's Manjit. On the first item, the credit you see in expenses, this quarter is largely due to some compensation adjustments that happen as part of the year-end process. And so that's -- there was a true-up for that. So that drove -- that was a recovery in the quarters, that's what you saw. On the other expenses that you mentioned, we do have some investments that we make in businesses over time that are reflected in that line. And one of those investments, obviously that's happening right now as IFRS 17. Along with some smaller investments, we're making the BG group so that's what's in that line.

I appreciate that you're doing your update -- IFRS update in 2000 --sorry, later on this month. But given the markets interest in -- is there anything you can offer in terms of what the transition could means the company's book value today?

Again, I think in a merit, it's as you say, there's a different components to that. I don't think it would really be helpful to give you a short answer to that. I think we want to take the time to walk you through the various elements of that and how they come together on May 31st.

Thank you.

Our next question comes from Tom MacKinnon of BMO Capital. Your line is open.

Good morning and thanks for taking my question. Just with respect to an expected dividend increase, it kind of just shows there's some recently good capital generation here. I don't think we've heard anything about kind of excess capital generation, since you gave us an $800 million annual figure several years ago. So is there anything you can share with us with respect to excess capital generation at Sun Life? And then I have a follow-up.

Good morning, Tom. It's Manjit, I'll take that. So as you know, we've maintained a strong capital position for many years and that's really underpinned by our disciplined approach to capital management. And as you say, an important component of that disciplined approach is generating strong capital from our diversified portfolio of businesses. And as Kevin outlined, we do have a very clear and consistent approach to how we manage our capital. We first invest in organic growth for our businesses and that consumes about 25 to 35% of our overall capital generated from underlying net income. Next, we focus on growing our dividend. And as we've talked about our payout range is 40 to 50% of underlying income. And so that leaves about 25% to 35% of underlying net income for excess capital generation to deploy before the impacts of market related items. And if you were to take a look at that for the past year, that would have been about a billion dollars before those market related items. So bit higher than the 800 we saw earlier.

Okay. That’s great. And Just with respect to some of the discussions with on group morbidity, is thinking that we should be looking at your more just confirming that might be more short-term related is in more COVID related, should the focus that would be more on unemployment. There is some sometimes any selection in group morbidity. So as long as we stay with relatively good employment levels, would you expect to group morbidity? Just the modest uptick that we saw in the quarter to come back in. As a result of unemployment being a fairly, fairly yielded here.

Tom, I think we can let Dan answer that first for the US and Jacques answers second for Canada.

Okay.

Sure. In the US, as you noted, unemployment is almost at a historically low level. In fact, there is 11.5 million open jobs in the US right now. So we don't think unemployment is really a factor here. We think there are other second order effect. As I mentioned, including employers requiring people to come back into the office who might not be fully comfortable doing that. That's likely a transient effect. The marketplace will find its equilibrium as labor and employers decide how they want to work together in the future. So we don't see that as necessarily a persistent impact.

And Tom, this is Jacques. Similar to Dan, I would say, we don't see employment levels as being a material issue at the moment to what we're seeing. It's really about duration, as I said earlier. I didn't mention it earlier, but mental health cases tend to be a bit longer than all other cases. With the access to care, it's really an issue of how quickly we can get people back to work. And at the moment I would say we don't expect that be durable a trend, but we're obviously watching it very closely, Tom, since it has obviously an impact on our results.

Okay. Can I -- if I could just squeeze one more as an impairment. In the quarter, if there's any color you can shed with respect to that and how we should be thinking about credit going forward.

Tom, this is Randy Brad, I will take that. Yeah, the impairments on or a couple of credits within our private fixed income portfolio. They were entirely idiosyncratic in nature. And so not indicative of any trends either within PF5. Specifically we're on the overall portfolio. I think overall, you will see another positive credit release this quarter, albeit down from prior quarters. I'm very comfortable at the competition of the portfolio. We have to see how markets play out as we look forward.

Okay, thanks.

Our next question comes from Lemar Persaud of Cormark. Your line is open.

Thanks. My question is probably most senior for Manjit and it's around I guess the outlook for earnings and surplus in that kind of rough a $100 million range. The rough target and may bounce around from quarter-to-quarter. But looking at that company that targeted the context of what we've seen over the past few quarters. Some of the challenges. Associated with generating AFS gains and seed investment in gains on what's putting out of the markets and rate environment. Does this feel like $100 million targeted is achievable in this market backdrop, I guess -- I guess the reason I have asked the as it you have to really go back like over a decade, defined a few quarters during up. Earnings on surplus this week, depending comments would be helpful.

Sure. Good morning, Lemar, it's Manjit. So as we mentioned in our earnings and surplus has kind of been in the $100 million range. And this quarter we saw $65 million. And there are a couple of items that led to lower result. We had lower mark-to-market seed investment losses. That really reflects the wider credit spreads you're seeing. There were some timing items in our investment income. We also had some higher debt costs reflecting the higher float rates on floating-rate debt, as well as the debt that we issued to fund DentaQuest, and as you mentioned, a lower AFS gains. So all together, that's what drove that number. And given the current environment that we're in, and as I mentioned in my prepared remarks, you'd expect the AFS gains to be more muted, which could result in surplus number below the $109 million range that we've been seeing previously. But the other thing that I mentioned obviously is also there is other components that also have different impacts on those markets related items. And we talked about it earlier in this call that could also provide some opportunities on the investment activity against side.

Okay, thanks. And then if I could squeeze another one in maybe just circling back there in earlier question around capital allocation for Kevin. Does management have the capacity to integrate DentaQuest while still digesting another acquisition or will M&A be off the table for a period of time?

It's a great question. Thanks. If we look at DentaQuest it is the second-largest acquisition we've ever made, but it's got a great management team. Dan, his team has executed on a large acquisition. And if you remember, it's really bringing a larger dental business into a smaller dental business alongside of ours. And so we're pretty confident that that integration is going to go well. And Manjit actually mentioned we've got the debt costs running through our earnings right now, but we don't have the benefit of the earnings coming through. So that's one thing that we're looking forward to. But from the overall capital position, it's obviously going to use a big chunk of the $4.7 billion we have at the Whole Co. We obviously see that we're in stressed times right now, and if you look at the economic conditions. But we are -- we do have a solid capital position and we continue to assess what the opportunities are. So it is a use of the majority of the capital at the Whole Co, when the deal closes. But we continue to have an eye on things that will improve the business, but we're -- we had that financial discipline will not change. And I think part of the financial discipline is looking at the economic conditions and what you’re purchasing.

Great, thanks.

Thank you. Our next question comes from Nigel D'Souza, Veritas Investment Research. Your question, please. Nigel D’Souza: Thank you. Good morning. I had follow-up for you first on SLC. I believe you mentioned a $150 million analyst tenuous fee revenue that could be generated from AUM not yet invested. Wondering if you had a period over which you expect to realize that? And what margin do you expect to earn on that revenue?

Hi, Nigel. Thanks for the question. When we raise money across our platform, the expected investment periods can vary. But I would say we'd expect to get that money invested over 12 to 24 months generally. In some funds, the investment period can be 3 years, so that can be the case. But I would say if it goes into the third year in a given fund, you've invested most of the assets by that time. The type of funds that lead to these non-fee earning assets are generally higher fee asset classes. So it's real estate. I'll turn it credit, its infrastructure where you raised money in a fund and then you drive down and as you drive down and invest money, you start raising the fees. As I said, those are higher fee asset. I'm not sure I prepared to give out a specific margin on that, but I would say that across our platform, those would be the higher fee assets that we manage. And therefore you know there are some additional costs to go those assets, but those would generally be are higher margin assets as well. Nigel D’Souza: Okay. So I think it's fair to assume it's probably above 20% based on what you disclosed on your fee-related earnings margin. And then the next question that I had was on your -- in fact, in investment activity, its favorable experience this quarter. And I was wondering if you could provide some color, is that mainly yield enhancement and how sustainable do you think this quarter's run rate is given the yield environment that we're seeing today?

Hi, Nigel. It's Randy Brown, I'll take that. Some of -- what you heard in prior quarters is that we had built some dry powder coming into this period with the expectation for the observation that credit spreads were near all-time adjusted lows, real rates were at all-time lows, equities were an all-time highs so we took some risk off the table and built dry powder. Some of that dry powder was deployed this quarter, some of that dry -- this past quarter. Some of that dry powder will be deployed as we see opportunities in Q2 and forward. And we are seeing opportunities with the dislocations in the market. And that was a nice -- another piece as mentioned was the strong PFI origination in spreads. And we are seeing that continue in Q2, its matter of deployment on the balance sheet in terms of how they flow. But we are seeing strong -- achieving strong spreads there as well. Nigel D’Souza: That's helping the last question that I have you and apologies if you already answered it. On the IFRS 17 update later this month, did you mentioned that you'd be providing an update on the expected impact underlying earnings or is that still further out?

I think we're going to cover a range of topics including our outlook for our medium term objectives. Nigel D’Souza: Okay, I appreciate it, thank you.

Thank you. We have no further questions at the time. I will turn things over to Mr. Bitton for closing remarks.

I would like to thank all of our participants today. Should you wish to listen to the rebroadcast, it will be available on our website later this afternoon. Thank you. And have a good day.

This concludes today's call. Thank you for your participation. You may now disconnect.